INFANT-MORTALITY AND MATERNAL VITAMIN-A-DEFICIENCY DURING HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION

被引:72
作者
SEMBA, RD
MIOTTI, PG
CHIPHANGWI, JD
LIOMBA, G
YANG, LP
SAAH, AJ
DALLABETTA, GA
HOOVER, DR
机构
[1] JOHNS HOPKINS UNIV,SCH MED,DEPT OPHTHALMOL,BALTIMORE,MD 21205
[2] JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC MICROBIOL & IMMUNOL,BALTIMORE,MD 21205
[3] JOHNS HOPKINS UNIV,SCH MED,DEPT EPIDEMIOL,BALTIMORE,MD 21205
[4] JOHNS HOPKINS UNIV,SCH MED,DEPT BIOSTAT,BALTIMORE,MD 21205
[5] JOHNS HOPKINS UNIV,SCH MED,CTR HUMAN NUTR,BALTIMORE,MD 21205
[6] JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD
[7] MALAWI MED COLL,BLANTYRE,MALAWI
[8] MINIST HLTH,AIDS CONTROL PROGRAMME,LILONGWE,MALAWI
关键词
D O I
10.1093/clinids/21.4.966
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The maternal factors that contribute to high mortality among infants born to women infected with human immunodeficiency virus (HIV) are unclear. We followed 474 HIV-infected mothers and their infants in Malawi from pregnancy through the infants' 12th month of life. Of the 474 HIV-infected pregnant women, 300 (63.3%) were deficient in vitamin A (serum level of vitamin A, <1.05 mu mol/L). Mean serum vitamin A levels among mothers whose infants died were 0.78 +/- 0.03 mu mol/L compared with 1.02 +/- 0.02 mu mol/L among mothers whose infants had survived for the first 12 months of life (P < .0001). The overall infant mortality rate was 28.7%. We divided HIV-positive mothers into six groups according to serum vitamin A levels (mu mol/L) as follows: group 1, <0.35; group 2, between 0.35 and 0.70; group 3, between 0.70 and 1.05; group 4, between 1.05 and 1.40; group 5, between 1.40 and 1.75; and group 6, > 1.75. Infant mortality rates for each group were 93.3%, 41.6%, 23.4%, 18.5%, 17.7%, and 14.2%, respectively (P < .0001). Maternal vitamin A deficiency during HIV infection may contribute to increased infant mortality.
引用
收藏
页码:966 / 972
页数:7
相关论文
共 50 条
[31]   IMMUNOPATHOGENESIS OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
IOACHIM, HL .
CANCER RESEARCH, 1990, 50 (17) :S5612-S5617
[32]   THE EPIDEMIOLOGY OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
GLASNER, PD ;
KASLOW, RA .
JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 1990, 58 (01) :13-21
[33]   NEUROSYPHILIS AND HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
WHITEFIELD, SG ;
EVERETT, AS ;
REIN, MF .
JOURNAL OF INFECTIOUS DISEASES, 1991, 164 (03) :609-609
[34]   NEPHROPATHY IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
ESFORZADO, N ;
FELIZ, T ;
ALMIRALL, J ;
TORRAS, A ;
MIRO, JM ;
GATELL, JM ;
REVERT, L .
MEDICINA CLINICA, 1992, 98 (20) :764-767
[35]   PSORIASIS AND HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
OBUCH, ML ;
MAURER, TA ;
BECKER, B ;
BERGER, TG .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1992, 27 (05) :667-673
[36]   TREATMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
LABROOY, J .
CURRENT OPINION IN NEUROLOGY AND NEUROSURGERY, 1990, 3 (02) :229-233
[38]   THE MOUTH IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
GREENSPAN, D ;
GREENSPAN, JS .
SEMINARS IN DERMATOLOGY, 1994, 13 (02) :144-150
[39]   IMMUNOPATHOGENESIS OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
POLI, G ;
PANTALEO, G ;
FAUCI, AS .
CLINICAL INFECTIOUS DISEASES, 1993, 17 :S224-S229
[40]   THERAPY FOR HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
HIRSCH, MS ;
DAQUILA, RT .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (23) :1686-1695